K H Kim1, M G Lee, D G Kim. 1. Department of Pharmacology, Yonsei University, College of Medicine, Seoul, Korea. Hwan444@yumc.yonsei.ac.kr
Abstract
CONCLUSION: Our results suggest that the cholecystokinin (CCK) receptor antagonist L-364,718 has a protective effect on taurocholate-induced pancreatitis, and thus, it is inferred that CCK may have a significant pathophysiological role in the early phase of pancreatitis. BACKGROUND: Conflicting results have been obtained from studies designed to determine the role of CCK in the initial stages of pancreatitis. METHODS: We evaluated the protective effect of the CCK receptor antagonist L-364,718 (devazepide) and of the trypsin inhibitor camostat, on taurocholate-induced pancreatitis in rats. L-364,718 (1 mg/kg) or camostat (200 mg/kg) was administered intragastrically 30 min before the induction of pancreatitis. RESULTS: Infusion of sodium taurocholate (50 mg/kg) into the pancreaticobiliary duct caused severe pancreatitis with marked hyperamylasemia and reduction of tissue enzyme content at 12 h postinfusion. Pretreatment with L-364,718, but not with camostat, caused significant improvement in signs of experimental pancreatitis based on tissue enzyme content and morphology. Compared with untreated pancreatitis, there was relatively well-preserved lobular architecture, less edema, less infiltration of inflammatory cells, and more zymogen granules after L-364,718 pretreatment. Moreover, the reduction of enzyme content owing to pancreatitis was ameliorated by L-364,718 pretreatment.
CONCLUSION: Our results suggest that the cholecystokinin (CCK) receptor antagonist L-364,718 has a protective effect on taurocholate-induced pancreatitis, and thus, it is inferred that CCK may have a significant pathophysiological role in the early phase of pancreatitis. BACKGROUND: Conflicting results have been obtained from studies designed to determine the role of CCK in the initial stages of pancreatitis. METHODS: We evaluated the protective effect of the CCK receptor antagonist L-364,718 (devazepide) and of the trypsin inhibitor camostat, on taurocholate-induced pancreatitis in rats. L-364,718 (1 mg/kg) or camostat (200 mg/kg) was administered intragastrically 30 min before the induction of pancreatitis. RESULTS: Infusion of sodium taurocholate (50 mg/kg) into the pancreaticobiliary duct caused severe pancreatitis with marked hyperamylasemia and reduction of tissue enzyme content at 12 h postinfusion. Pretreatment with L-364,718, but not with camostat, caused significant improvement in signs of experimental pancreatitis based on tissue enzyme content and morphology. Compared with untreated pancreatitis, there was relatively well-preserved lobular architecture, less edema, less infiltration of inflammatory cells, and more zymogen granules after L-364,718 pretreatment. Moreover, the reduction of enzyme content owing to pancreatitis was ameliorated by L-364,718 pretreatment.
Authors: R S Chang; V J Lotti; R L Monaghan; J Birnbaum; E O Stapley; M A Goetz; G Albers-Schönberg; A A Patchett; J M Liesch; O D Hensens Journal: Science Date: 1985-10-11 Impact factor: 47.728
Authors: W A Hoogerwerf; L Zou; M Shenoy; D Sun; M A Micci; H Lee-Hellmich; S Y Xiao; J H Winston; P J Pasricha Journal: J Neurosci Date: 2001-11-15 Impact factor: 6.167
Authors: Tianming Le; John F Eisses; Kathryn L Lemon; John A Ozolek; Derek A Pociask; Abrahim I Orabi; Sohail Z Husain Journal: Pancreas Date: 2015-04 Impact factor: 3.327